8-K: Brainstorm Cell Therapeutics Receives FDA Clearance for Phase 3b NurOwn ALS Trial

Brainstorm Cell Therapeutics has received FDA clearance to initiate a Phase 3b clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).

Summary

• Brainstorm Cell Therapeutics announced that the FDA has cleared its Phase 3b clinical trial of NurOwn for ALS.
• The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA).
• The company plans to enroll approximately 200 participants at leading academic medical centers.
• The trial will consist of a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension where all participants will receive NurOwn.
• The primary endpoint is the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R).
• Brainstorm is actively working to secure funding through multiple avenues, including non-dilutive grants, to ensure the timely and successful launch of this critical study.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the FDA clearance, which is a significant milestone. However, the need to secure funding and the inherent risks in clinical trials temper the overall sentiment.

Positives

• FDA clearance for the Phase 3b trial of NurOwn is a significant milestone.
• The trial design has been agreed upon with the FDA under a Special Protocol Assessment (SPA).
• The open-label extension allows all participants to receive NurOwn.
• Brainstorm is actively seeking funding to support the trial.

Risks

• The company's ability to raise additional capital is a risk factor.
• Future regulatory approval of NurOwn is not guaranteed.
• Interactions with the FDA may not have productive outcomes.

Future Outlook

Brainstorm will provide ongoing updates as the trial progresses and key milestones are achieved, and is actively working to secure funding through multiple avenues, including non-dilutive grants, to ensure the timely and successful launch of this critical study.

Management Comments

• Chaim Lebovits, President and Chief Executive Officer of BrainStorm, stated that the FDA clearance is a defining milestone for BrainStorm and the ALS community.
• He also mentioned that the company is positioned to swiftly activate clinical sites and is diligently preparing to enroll the first patient in the Phase 3b trial.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for ALS, a debilitating neurodegenerative disease. The FDA clearance allows Brainstorm to advance its NurOwn therapy, potentially offering a new treatment option for patients.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards without knowing the specific details of the trial design and the historical performance of similar ALS treatments.
• However, the use of a Special Protocol Assessment (SPA) with the FDA suggests that the trial design has been carefully considered and is likely to meet regulatory requirements.
• Other companies developing ALS treatments include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio), and Mitsubishi Tanabe Pharma (Edaravone).

Stakeholder Impact

• Shareholders: The FDA clearance is likely to be viewed positively by shareholders.
• Patients: The trial offers hope for a new treatment option for ALS patients.
• Employees: The trial represents a significant step forward for the company and its employees.

Next Steps

• Brainstorm will activate clinical sites in a phased manner.
• The company will prepare to enroll the first patient in the Phase 3b trial.
• Brainstorm will continue to seek funding for the trial.
• The company will provide further ongoing updates as the trial progresses and key milestones are achieved.

Key Dates

Keywords

NurOwn, ALS, Phase 3b clinical trial, Brainstorm Cell Therapeutics, FDA clearance, amyotrophic lateral sclerosis, MSC-NTF cells, Special Protocol Assessment, clinical trial